Agree with the primacy of results: delivering successful RCT's and approvals etc. I think they have done a reasonable job so far in this regard, except perhaps for the bronchiectasis trial. I don't agree with Postman that the cash position and burn is a major factor, especially when bronchitol is close to market in both Aust/ Europe. The study results for CF were impressive and undeniable from a clinical viewpoint.
Agree with the primacy of results: delivering successful RCT's...
-
- There are more pages in this discussion • 15 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
